Loading…
P1388: EFFECTIVENESS AND SAFETY OUTCOMES IN PATIENTS WITH EBV+ PTLD TREATED WITH ALLOGENEIC EBV‐SPECIFIC T‐CELL IMMUNOTHERAPY (TABELECLEUCEL) UNDER AN EXPANDED ACCESS PROGRAM IN EUROPE
Saved in:
Published in: | HemaSphere 2023-08, Vol.7 (S3), p.e8073255-n/a |
---|---|
Main Authors: | , , , , , , , , , , , , , |
Format: | Article |
Language: | English |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
cited_by | |
---|---|
cites | |
container_end_page | n/a |
container_issue | S3 |
container_start_page | e8073255 |
container_title | HemaSphere |
container_volume | 7 |
creator | Choquet, Sylvain Clark, Andrew Renard, Cécile Uttenthal, Ben Chaganti, Sridhar Ulrich Trappe, Ralf Comoli, Patrizia Duan, Xinyuan Xing, Baodong Wu, Charley Gamelin, Laurence Terwey, Jan‐Henrik Friedetzky, Anke Dierickx, Daan |
description | |
doi_str_mv | 10.1097/01.HS9.0000972440.80732.55 |
format | article |
fullrecord | <record><control><sourceid>wiley_doaj_</sourceid><recordid>TN_cdi_doaj_primary_oai_doaj_org_article_aa027855236c4b1ea54bea970adf8954</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><doaj_id>oai_doaj_org_article_aa027855236c4b1ea54bea970adf8954</doaj_id><sourcerecordid>HEM3BF07457</sourcerecordid><originalsourceid>FETCH-LOGICAL-c2857-e3f1a8f795ef1055ca9ca55f41a9d74dce40eede7dce84028ebddf8e545ce6873</originalsourceid><addsrcrecordid>eNqVkk9u1DAYxSMEElXpHSxWIDTBTuxx3A3KeL5pImWSKHEKXVmexCmppp0qaUHdcQQOxGk4CZ4OArrEG_v7835-i-d5rwn2CRb8PSZ-UgsfuyN4QCn2I8zDwGfsmXcUMB7MREDJ83_eL72Tabpy-0QIMQ_4kfejJGEUnSJYrUCq9BxyqGsU50tUxytQF6holCzWUKM0R2WsUshVjT6mKkGwOH-HSpUtkaogVrA8tOMsK84cJpX7jZ_fvtclyHTlSuUKCVmG0vW6yQuVQBWXF-iNiheQgcygcdO3qMmXUDkLCD6VzojjxlLuXZVVcVbF670TaKqihFfei95sJ3vy-z72GudZJjPnIJVxNmuDiPGZDXtiop4LZnuCGWuNaA1jPSVGdJx2raXY2s5y94ooDiK76bo-soyy1s4jHh576YHb7cyVvh2HazM-6J0Z9GNjN15qM94N7dZqY3DAI8aCcN7SDbGG0Y01gmPjiIJRx_pwYN3eb66t-_HmbjTbJ9Cnk5vhs77cfdEE0xDPBXGE0wOhHXfTNNr-j5hgvQ-GxkS7YOi_wdCPwdCMObE8iL8OW_vwH0qdwDpcrDCnjIe_AC9ltOI</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>P1388: EFFECTIVENESS AND SAFETY OUTCOMES IN PATIENTS WITH EBV+ PTLD TREATED WITH ALLOGENEIC EBV‐SPECIFIC T‐CELL IMMUNOTHERAPY (TABELECLEUCEL) UNDER AN EXPANDED ACCESS PROGRAM IN EUROPE</title><source>Wiley Online Library Open Access</source><source>PubMed Central</source><creator>Choquet, Sylvain ; Clark, Andrew ; Renard, Cécile ; Uttenthal, Ben ; Chaganti, Sridhar ; Ulrich Trappe, Ralf ; Comoli, Patrizia ; Duan, Xinyuan ; Xing, Baodong ; Wu, Charley ; Gamelin, Laurence ; Terwey, Jan‐Henrik ; Friedetzky, Anke ; Dierickx, Daan</creator><creatorcontrib>Choquet, Sylvain ; Clark, Andrew ; Renard, Cécile ; Uttenthal, Ben ; Chaganti, Sridhar ; Ulrich Trappe, Ralf ; Comoli, Patrizia ; Duan, Xinyuan ; Xing, Baodong ; Wu, Charley ; Gamelin, Laurence ; Terwey, Jan‐Henrik ; Friedetzky, Anke ; Dierickx, Daan</creatorcontrib><identifier>ISSN: 2572-9241</identifier><identifier>EISSN: 2572-9241</identifier><identifier>DOI: 10.1097/01.HS9.0000972440.80732.55</identifier><language>eng</language><publisher>Philadelphia, PA: Lippincott Williams & Wilkins</publisher><ispartof>HemaSphere, 2023-08, Vol.7 (S3), p.e8073255-n/a</ispartof><rights>Copyright © 2023 The Author(s).</rights><rights>Copyright © 2023 The Author(s). Published by Wolters Kluwer Health, Inc. 2023</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC10430691/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC10430691/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,723,776,780,881,11541,27901,27902,46027,46451,53766,53768</link.rule.ids></links><search><creatorcontrib>Choquet, Sylvain</creatorcontrib><creatorcontrib>Clark, Andrew</creatorcontrib><creatorcontrib>Renard, Cécile</creatorcontrib><creatorcontrib>Uttenthal, Ben</creatorcontrib><creatorcontrib>Chaganti, Sridhar</creatorcontrib><creatorcontrib>Ulrich Trappe, Ralf</creatorcontrib><creatorcontrib>Comoli, Patrizia</creatorcontrib><creatorcontrib>Duan, Xinyuan</creatorcontrib><creatorcontrib>Xing, Baodong</creatorcontrib><creatorcontrib>Wu, Charley</creatorcontrib><creatorcontrib>Gamelin, Laurence</creatorcontrib><creatorcontrib>Terwey, Jan‐Henrik</creatorcontrib><creatorcontrib>Friedetzky, Anke</creatorcontrib><creatorcontrib>Dierickx, Daan</creatorcontrib><title>P1388: EFFECTIVENESS AND SAFETY OUTCOMES IN PATIENTS WITH EBV+ PTLD TREATED WITH ALLOGENEIC EBV‐SPECIFIC T‐CELL IMMUNOTHERAPY (TABELECLEUCEL) UNDER AN EXPANDED ACCESS PROGRAM IN EUROPE</title><title>HemaSphere</title><issn>2572-9241</issn><issn>2572-9241</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><sourceid>24P</sourceid><sourceid>DOA</sourceid><recordid>eNqVkk9u1DAYxSMEElXpHSxWIDTBTuxx3A3KeL5pImWSKHEKXVmexCmppp0qaUHdcQQOxGk4CZ4OArrEG_v7835-i-d5rwn2CRb8PSZ-UgsfuyN4QCn2I8zDwGfsmXcUMB7MREDJ83_eL72Tabpy-0QIMQ_4kfejJGEUnSJYrUCq9BxyqGsU50tUxytQF6holCzWUKM0R2WsUshVjT6mKkGwOH-HSpUtkaogVrA8tOMsK84cJpX7jZ_fvtclyHTlSuUKCVmG0vW6yQuVQBWXF-iNiheQgcygcdO3qMmXUDkLCD6VzojjxlLuXZVVcVbF670TaKqihFfei95sJ3vy-z72GudZJjPnIJVxNmuDiPGZDXtiop4LZnuCGWuNaA1jPSVGdJx2raXY2s5y94ooDiK76bo-soyy1s4jHh576YHb7cyVvh2HazM-6J0Z9GNjN15qM94N7dZqY3DAI8aCcN7SDbGG0Y01gmPjiIJRx_pwYN3eb66t-_HmbjTbJ9Cnk5vhs77cfdEE0xDPBXGE0wOhHXfTNNr-j5hgvQ-GxkS7YOi_wdCPwdCMObE8iL8OW_vwH0qdwDpcrDCnjIe_AC9ltOI</recordid><startdate>20230808</startdate><enddate>20230808</enddate><creator>Choquet, Sylvain</creator><creator>Clark, Andrew</creator><creator>Renard, Cécile</creator><creator>Uttenthal, Ben</creator><creator>Chaganti, Sridhar</creator><creator>Ulrich Trappe, Ralf</creator><creator>Comoli, Patrizia</creator><creator>Duan, Xinyuan</creator><creator>Xing, Baodong</creator><creator>Wu, Charley</creator><creator>Gamelin, Laurence</creator><creator>Terwey, Jan‐Henrik</creator><creator>Friedetzky, Anke</creator><creator>Dierickx, Daan</creator><general>Lippincott Williams & Wilkins</general><general>Wiley</general><scope>24P</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>5PM</scope><scope>DOA</scope></search><sort><creationdate>20230808</creationdate><title>P1388: EFFECTIVENESS AND SAFETY OUTCOMES IN PATIENTS WITH EBV+ PTLD TREATED WITH ALLOGENEIC EBV‐SPECIFIC T‐CELL IMMUNOTHERAPY (TABELECLEUCEL) UNDER AN EXPANDED ACCESS PROGRAM IN EUROPE</title><author>Choquet, Sylvain ; Clark, Andrew ; Renard, Cécile ; Uttenthal, Ben ; Chaganti, Sridhar ; Ulrich Trappe, Ralf ; Comoli, Patrizia ; Duan, Xinyuan ; Xing, Baodong ; Wu, Charley ; Gamelin, Laurence ; Terwey, Jan‐Henrik ; Friedetzky, Anke ; Dierickx, Daan</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c2857-e3f1a8f795ef1055ca9ca55f41a9d74dce40eede7dce84028ebddf8e545ce6873</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Choquet, Sylvain</creatorcontrib><creatorcontrib>Clark, Andrew</creatorcontrib><creatorcontrib>Renard, Cécile</creatorcontrib><creatorcontrib>Uttenthal, Ben</creatorcontrib><creatorcontrib>Chaganti, Sridhar</creatorcontrib><creatorcontrib>Ulrich Trappe, Ralf</creatorcontrib><creatorcontrib>Comoli, Patrizia</creatorcontrib><creatorcontrib>Duan, Xinyuan</creatorcontrib><creatorcontrib>Xing, Baodong</creatorcontrib><creatorcontrib>Wu, Charley</creatorcontrib><creatorcontrib>Gamelin, Laurence</creatorcontrib><creatorcontrib>Terwey, Jan‐Henrik</creatorcontrib><creatorcontrib>Friedetzky, Anke</creatorcontrib><creatorcontrib>Dierickx, Daan</creatorcontrib><collection>Wiley Online Library Open Access</collection><collection>CrossRef</collection><collection>PubMed Central (Full Participant titles)</collection><collection>DOAJ Directory of Open Access Journals</collection><jtitle>HemaSphere</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Choquet, Sylvain</au><au>Clark, Andrew</au><au>Renard, Cécile</au><au>Uttenthal, Ben</au><au>Chaganti, Sridhar</au><au>Ulrich Trappe, Ralf</au><au>Comoli, Patrizia</au><au>Duan, Xinyuan</au><au>Xing, Baodong</au><au>Wu, Charley</au><au>Gamelin, Laurence</au><au>Terwey, Jan‐Henrik</au><au>Friedetzky, Anke</au><au>Dierickx, Daan</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>P1388: EFFECTIVENESS AND SAFETY OUTCOMES IN PATIENTS WITH EBV+ PTLD TREATED WITH ALLOGENEIC EBV‐SPECIFIC T‐CELL IMMUNOTHERAPY (TABELECLEUCEL) UNDER AN EXPANDED ACCESS PROGRAM IN EUROPE</atitle><jtitle>HemaSphere</jtitle><date>2023-08-08</date><risdate>2023</risdate><volume>7</volume><issue>S3</issue><spage>e8073255</spage><epage>n/a</epage><pages>e8073255-n/a</pages><issn>2572-9241</issn><eissn>2572-9241</eissn><cop>Philadelphia, PA</cop><pub>Lippincott Williams & Wilkins</pub><doi>10.1097/01.HS9.0000972440.80732.55</doi><tpages>2</tpages><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 2572-9241 |
ispartof | HemaSphere, 2023-08, Vol.7 (S3), p.e8073255-n/a |
issn | 2572-9241 2572-9241 |
language | eng |
recordid | cdi_doaj_primary_oai_doaj_org_article_aa027855236c4b1ea54bea970adf8954 |
source | Wiley Online Library Open Access; PubMed Central |
title | P1388: EFFECTIVENESS AND SAFETY OUTCOMES IN PATIENTS WITH EBV+ PTLD TREATED WITH ALLOGENEIC EBV‐SPECIFIC T‐CELL IMMUNOTHERAPY (TABELECLEUCEL) UNDER AN EXPANDED ACCESS PROGRAM IN EUROPE |
url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-30T04%3A45%3A38IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-wiley_doaj_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=P1388:%20EFFECTIVENESS%20AND%20SAFETY%20OUTCOMES%20IN%20PATIENTS%20WITH%20EBV+%20PTLD%20TREATED%20WITH%20ALLOGENEIC%20EBV%E2%80%90SPECIFIC%20T%E2%80%90CELL%20IMMUNOTHERAPY%20(TABELECLEUCEL)%20UNDER%20AN%20EXPANDED%20ACCESS%20PROGRAM%20IN%20EUROPE&rft.jtitle=HemaSphere&rft.au=Choquet,%20Sylvain&rft.date=2023-08-08&rft.volume=7&rft.issue=S3&rft.spage=e8073255&rft.epage=n/a&rft.pages=e8073255-n/a&rft.issn=2572-9241&rft.eissn=2572-9241&rft_id=info:doi/10.1097/01.HS9.0000972440.80732.55&rft_dat=%3Cwiley_doaj_%3EHEM3BF07457%3C/wiley_doaj_%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c2857-e3f1a8f795ef1055ca9ca55f41a9d74dce40eede7dce84028ebddf8e545ce6873%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true |